SCHEMBL3299123

SCHEMBL3299123

CC(OC(=O)C(Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1)C(=O)N1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.60
SLC22A12 Q96S37 1/20 0.56
LMNA P02545 3/20 0.41
HTT P42858 3/20 0.41
MAPT P10636 2/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
DPP4 P27487 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
MGLL Q99685 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CNR1 P21554 1/20 0.39
MC4R P32245 2/20 0.39
KLRK1 P26718 1/20 0.38
MICA Q29983 1/20 0.38
RAET1L Q5VY80 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12189840 1.00 PPARG (0.60) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL3299127 1.00 PPARG (0.60) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL3299728 1.00 PPARG (0.60) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL13359395 0.96 PPARG (0.62) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL13324898 0.96 PPARG (0.62) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL13324897 0.92 PPARG (0.57) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL16502054 0.92 PPARG (0.57) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL13359396 0.92 PPARG (0.57) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL14547522 0.91 PPARG (0.61) PPARGSLC22A12LMNAHTTMAPT
SCHEMBL13359397 0.91 PPARG (0.61) PPARGSLC22A12LMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160075636-A1 Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester CYMABAY THERAPEUTICS, INC. (US) 2016-03-17 US disclosed
US-8541614-B2 Process for the preparation of (−)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester METABOLEX, INC. (US) 2013-09-24 US disclosed
US-7714131-B2 Process for the stereoselective preparation of (−)-halofenate and derivatives thereof METABOLEX, INC. (US) 2010-05-11 US disclosed
US-20100093854-A1 PROCESS FOR THE PREPARATION OF (-)-(4-CHLORO-PHENYL)-(3-TRIFLUOROMETHYL-PHENOXY)-ACETIC ACID 2-ACETYLAMINO-ETHYL ESTER DIATEX, INC. 2010-04-15 US disclosed
US-20070072858-A1 Process for the stereoselective preparation of (-)-halofenate and derivatives thereof METABOLEX, INC. (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075636-A1 Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester PC, ACACA, ACACB PPARG 136/4885SLC22A12 2169/4885LMNA 2514/4885
US-20070072858-A1 Process for the stereoselective preparation of (-)-halofenate and derivatives thereof CCNY, C1S, CBR3 PPARG 1448/4885SLC22A12 2018/4885LMNA 817/4885
US-20100093854-A1 PROCESS FOR THE PREPARATION OF (-)-(4-CHLORO-PHENYL)-(3-TRIFLUOROMETHYL-PHENOXY)-ACETIC ACID 2-ACETYLAMINO-ETHYL ESTER PC, ACACA, ACACB PPARG 136/4885SLC22A12 2169/4885LMNA 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.